A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
NCT: NCT07816185 · RECRUITING
NCT IDNCT07816185
StatusRECRUITING
Start Date2026-08-31
Completion2029-08-31
SponsorPulmovant, Inc. (INDUSTRY)
First posted
Last updated
Brief Summary
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Frequently Asked Questions
What is A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)?
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) is a clinical trial registered under NCT07816185. Current status: RECRUITING.
What is the status of NCT07816185?
The current status of NCT07816185 (A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)) is: RECRUITING.
When did A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) start?
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) started on 2026-08-31.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.